Market research
MTNB Matinas BioPharma Holdings, Inc
AMEX USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 30
- Dividend yield
- Not available
- Beta
- 1.75
Profile
Company facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US5768103039
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 30
- Dividend yield
- Not available
- Beta
- 1.75
About
About Matinas BioPharma Holdings, Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MTNB discussion.
5 years, 4 months ago
Matinas BioPharma Holdings, Inc is currently in a long term downtrend where the price is trading 28.4% below its 200 day moving average.
From a valuation standpoint, the stock is 0.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1330.6.
Matinas BioPharma Holdings, Inc's total revenue rose by inf% to $62K since the same quarter in the previous year.
Its net income has increased by 100.3% to $16K since the same quarter in the previous year.
Finally, its free cash flow grew by 18.7% to $-4M since the same quarter in the previous year.
Based on the above factors, Matinas BioPharma Holdings, Inc gets an overall score of 4/5.